Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.35 +8.1%	$5.30	$1.67 ▼ $7.29	$524.23M	0.94	4.96 million shs	6.03 million shs
BCYC Bicycle Therapeutics	$7.10 +0.1%	$7.71	$6.10 ▼ $28.67	$491.70M	1.44	269,982 shs	210,802 shs
GOSS Gossamer Bio	$2.34 +7.8%	$1.65	$0.66 ▼ $2.35	$532.07M	1.96	2.92 million shs	4.89 million shs
PFSCF ProMetic Life Sciences	$5.47	$5.47	$5.47 ▼ $352.00	$127.45M	2.46	279 shs	N/A

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	+9.18%	-3.60%	+42.67%	+184.57%
BCYC Bicycle Therapeutics	0.00%	-4.57%	-17.44%	-11.80%	-68.49%
GOSS Gossamer Bio	0.00%	+19.39%	+31.46%	+95.00%	+148.94%
PFSCF ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.5258 of 5 stars	3.6	1.0	0.0	0.0	3.3	1.7	0.6
BCYC Bicycle Therapeutics	3.6901 of 5 stars	3.4	4.0	0.0	0.0	3.2	4.2	0.6
GOSS Gossamer Bio	3.29 of 5 stars	3.5	1.0	0.0	4.7	0.0	1.7	0.0
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.17	Buy	$23.25	334.58% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$22.22	212.99% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	263.25% Upside
PFSCF ProMetic Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PFSCF, GOSS, BCYC, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ATYR aTyr Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $17.00
8/12/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $10.00
8/12/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $13.00
8/11/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$27.00
8/11/2025	BCYC Bicycle Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $44.00
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,279.33	N/A	N/A	$0.76 per share	7.04
BCYC Bicycle Therapeutics	$35.28M	13.94	N/A	N/A	$9.66 per share	0.73
GOSS Gossamer Bio	$114.70M	4.64	N/A	N/A	($0.20) per share	-11.70
PFSCF ProMetic Life Sciences	$36.55M	3.49	N/A	N/A	($67.63) per share	-0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	11/6/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.51	N/A	N/A	N/A	-1,257.00%	-32.43%	-26.80%	10/30/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	11/6/2025 (Estimated)
PFSCF ProMetic Life Sciences	-$150.73M	N/A	0.00	∞	N/A	-894.02%	-3,350.55%	-67.76%	N/A

Latest PFSCF, GOSS, BCYC, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
BCYC Bicycle Therapeutics	N/A	10.39	10.39
GOSS Gossamer Bio	6.70	4.40	4.40
PFSCF ProMetic Life Sciences	N/A	0.95	0.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
BCYC Bicycle Therapeutics	86.15%
GOSS Gossamer Bio	81.23%
PFSCF ProMetic Life Sciences	0.10%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
BCYC Bicycle Therapeutics	22.90%
GOSS Gossamer Bio	6.70%
PFSCF ProMetic Life Sciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
PFSCF ProMetic Life Sciences	50	23.31 million	N/A	Not Optionable

PFSCF, GOSS, BCYC, and ATYR Headlines

Recent News About These Companies

Plant Sciences

August 10, 2023 | uwyo.eduU

Social Sciences

July 29, 2023 | news.yale.eduN

Overcoming DNA Degradation in Forensic Science

June 7, 2023 | news-medical.netN

The UK Life Sciences Real Estate Annual Conference

February 23, 2023 | bisnow.comB

New 200-acre Life Sciences Development Proposed in Plano

February 15, 2023 | dmagazine.comD

Life Sciences Keeps Boston as a Top 10 Market

January 29, 2023 | globest.comG

There's Been No Shortage Of Growth Recently For TMC Life Sciences Berhad's (KLSE:TMCLIFE) Returns On Capital

January 28, 2023 | finance.yahoo.com

India's Glenmark Life Sciences Q3 profit rises 1% on API strength

January 28, 2023 | reuters.com

US Life Sciences Market Ends 2022 on Solid Ground: Report

January 28, 2023 | commercialobserver.comC

Opportunities aplenty in the life sciences sector

January 5, 2023 | irishtimes.com

Life Sciences Funds Post Mixed Results in September

October 16, 2022 | institutionalinvestor.comI

What Recession? Life Sciences Continues To Boom

September 24, 2022 | globest.comG

Here's what to expect from Prometic Life Sciences's earnings report

May 10, 2022 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSCF, GOSS, BCYC, and ATYR Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.35 +0.40 (+8.08%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.38 +0.03 (+0.47%)

As of 08/22/2025 07:56 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Bicycle Therapeutics NASDAQ:BCYC

$7.10 +0.01 (+0.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.16 +0.06 (+0.77%)

As of 08/22/2025 07:59 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Gossamer Bio NASDAQ:GOSS

$2.34 +0.17 (+7.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.04 (-1.71%)

As of 08/22/2025 07:40 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)

As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time